Quest Diagnostics competitors

Michael F. Mahoney is a Director on the board of the Boys & Girls Club of Boston. He is the Chairman and CEO of Boston Scientific.

Mr. Schechter has served as a director of the Company since April 1, 2013. Mr. Schechter is an Executive Vice President of Merck & Co., Inc. and since 2010 has been President of Merck’s Global Human Health Division, which includes the company’s worldwide pharmaceutical and vaccine businesses. He is a member of Merck’s executive committee and pharmaceutical and vaccines operating committee. Prior to becoming President, Global Human Health, Mr. Schechter served as President, Global Pharmaceutical Business from 2007 to 2010. Mr. Schechter’s extensive experience at Merck includes global and U.S.-focused leadership roles spanning sales, marketing, and managed markets, as well as business and product development. Mr. Schechter serves on the Board of Directors for the European Federation of Pharmaceutical Industries and Associations. He is a Board Member for Water.org and an Executive Board Member for the National Alliance for Hispanic Health.

Sherrie Perkins is a Co-Executive Director at ARUP Institute for Clinical & Experimental Pathology, Chief Executive Officer at ARUP Laboratories, and Head:Clinical Pathology at University of Utah Medical School. She has worked as Professor at University of Utah Medical School, Senior VP:Research & Development at ARUP Laboratories, and Chief Medical Officer at ARUP Laboratories. Sherrie studied at WASHINGTON UNIVERSITY and University of Miami.

Jon Cohen is a SVP at QUEST DIAGNOSTICS INC, Chief Executive Officer at Bioreference Laboratories, and Executive Chairman at Bioreference Laboratories and is based in Elmwood Park, New Jersey.

Mr. James E. Fantus is a President and Chief Executive Officer at CLINICAL LABORATORY PARTNERS and is based in United States.

Jake Orville has 20+ years of diagnostic, life science and medical device management experience within both established and emerging markets. As the General Manager of Pipeline at Exact Sciences, Jake leads the company's efforts to develop and advance solutions for earlier detection and life changing answers across the cancer continuum. Prior to Exact Sciences, Jake co-founded Cleveland HeartLab, Inc. (CHL) and served as the CEO from inception to exit. CHL was spun-out of the Cleveland Clinic to develop and rapidly commercialize unique diagnostic technologies, with applications in cardiovascular and inflammatory indications. CHL was acquired by Quest Diagnostics in December 2017. Jake Served as the General Manager of the Cardiometabolic & Endocrinology Franchise at Quest. Under Jake’s leadership, CHL was recognized as Ohio’s Venture of the Year (2012); received an Economic Impact Award by the city of Cleveland for job creation (2013) and was recognized as an Inc. 500 fastest growing private company in the US (2014). Jake has been recognized as a Top 50 Smart Leader by Smart Magazine and received the Annual Innovation Award in 2018 Prior to co-founding Cleveland HeartLab, Jake was CEO of Prognostix and held Senior Management positions with two publically traded companies (NextGen Sciences - AIM NGG.L; Third Wave Technologies - Nasdaq TWTI). He is a co-founder of Viridian Medical and Tolera Therapeutics and currently sits on the Board of Directors for The Wisconsin Women’s Health Foundation. Jake has raised capital from multiple sources, including top tier venture funds, strategic and international investors as well as angels, family offices and state funding sources. A well recognized entrepreneur, he has given many lectures on innovation, commercialization, early stage ventures, technology transfer and intellectual property. Jake received his Bachelor of Arts from the University of Massachusetts, Amherst and his MBA from the University of Wisconsin, Madison.